The antiparkinsonian action of the prolyl endopeptidase inhibitor in mice
Abstract
Prolyl endopeptidase is involved in neurodegeneration, proliferation, neuroinflammation and neuron differentiation. It has been observed that severity of neurodegenerative process correlates with increasing level of prolyl endopeptidase in the brain. According to the recent research, prolyl endopeptidase might interact with prion-like proteins, which are believed to be the key players in the development of neurodegenerative diseases. Consequently, prolyl endopeptidase inhibitors might be a promising group of chemicals to study in neurodegenerative diseases, particularly Parkinson’s disease. The aim of the research was to determine the effects of a new inhibitor of prolyl endopeptidase by haloperidol catalepsy test in SHK mice and MPTP induced Parkinson-like syndrome in C57Bl/6 mice. Neurotoxin MPTP (30 mg/kg, single intraperitoneal injection) was used to provide the specific dopaminergic damage in C57Bl/6 mice. As a result, the compound reduces the severity of main extrapyramidal symptoms: rigidity and motor deficits. However, the anticataleptic activity was not found. According to our results, the prolyl endopeptidase inhibitor does not effect on the dopaminergic neurons directly, but provides neuroprotection to the neurons.
About the Authors
A. P. Kalinina
FSBI Zakusov Institute of Pharmacology
Russian Federation
Russian Federation
Laboratory of Psychopharmacology.
Baltiyskaya ul. 8, Moscow, 125315I. G. Kapitsa
FSBI Zakusov Institute of Pharmacology
Russian Federation
Russian Federation
Laboratory of Psychopharmacology.
Baltiyskaya ul. 8, Moscow, 125315E. A. Ivanova
FSBI Zakusov Institute of Pharmacology
Russian Federation
Russian Federation
Laboratory of Psychopharmacology.
Baltiyskaya ul. 8, Moscow, 125315T. A. Voronina
FSBI Zakusov Institute of Pharmacology
Russian Federation
Russian Federation
Laboratory of Psychopharmacology.
Baltiyskaya ul. 8, Moscow, 125315References
1. Babkova K., Korabecny J., Soukup O., Nepovimova E, Jun D, Kuca K Prolyl oligopeptidase and its role in the organism: attention to the most promising and clinically relevant inhibitors // Future Med. Chem. 2017. Vol. 9. N 10. P. 1015-1038.
2. Myohanen T.T., Hannula M.J., Van Elzen R., Gerard M, Van Der Veken P, Garcia-Horsman J.A., Baekelandt V., Mannisto P.T., Lambeir A.M. A prolyl oligopeptidase inhibitor, KYP-2047, reduces alpha-synuclein protein levels and aggregates in cellular and animal models of Parkinson’s disease // Brit. J. Pharmacol. 2012. Vol. 166. N 3. P. 1097-1113.
3. Беседин Д.В., Руденская Г.Н. Пролинспец-ифичные эндопептидазы // Биоорг. хим. 2003. Т. 29. № 1. С. 3-20.
4. Myohanen T.T., Venalainen J.I., Tupala E, Garcia-Horsman J.A., Miettinen R, Mannisto P.T. Distribution of immunoreactive prolyl oligopeptidase in human and rat brain // Neurochem. Res. 2007. Vol. 32. N 8. P. 1365-1374.
5. Tenorio-Laranga J., Montoliu C, Urios A., Hernandez-Rabaza V., Ahabrach H, Garcia-Horsman J.A., Felipo V. The expression levels of prolyl oligopeptidase responds not only to neuroinflammation but also to systemic inflammation upon liver failure in rat models and cirrhotic patients // J. Neuroinflamm. 2015. Vol. 12: 183.
6. Penttinen A., Tenorio-Laranga J., Siikanen A., Morawski M., Rossner S., Garcia-Horsman J.A. Prolyl oligopeptidase: a rising star on the stage of neuroinflammation research // CNS Neurol. Disord. Drug Targets. 2011. Vol. 10. N 3. P. 340-348.
7. Natunen T.A., Gynther M., Rostalski H., Jaako K., Jalkanen A.J. Extracellular prolyl oligopeptidase derived from activated microglia is a potential neuroprotection target // Basic Clin. Pharmacol. 2019. Vol. 124. N 1. P. 40-49.
8. Hofling C., Kulesskaya N., Jaako K., Peltonen I., Mannisto P.T., Nurmi A., Vartiainen N., Morawski M., Zharkovsky A., Voikar V., Rossner S., Garcia-Horsman J.A. Deficiency of prolyl oligopeptidase in mice disturbs synaptic plasticity and reduces anxietylike behaviour, body weight, and brain volume // Eur. Neuropsychopharm. 2016. Vol. 26. N 6. P. 10481061.
9. Hannula M.J., Myohanen T.T., Tenorio-Laranga J., Mannisto P.T., Garcia-Horsman J.A. Prolyl oligopeptidase colocalizes with alpha-synuclein, beta-amyloid, tau protein and astroglia in the post-mortem brain samples with Parkinson’s and Alzheimer’s diseases // Neuroscience. 2013. Vol. 242. P. 140-150.
10. Mannisto P.T., Venalainen J., Jalkanen A., Garcia-Horsman J.A. Prolyl oligopeptidase: a potential target for the treatment of cognitive disorders // Drug News Perspect. 2007. Vol. 20. N 5. P. 293-305.
11. Dokleja L., Hannula M.J., Myohanen T.T. Inhibition of prolyl oligopeptidase increases the survival of alpha-synuclein overexpressing cells after rotenone exposure by reducing alpha-synuclein oligomers // Neurosci. Lett. 2014. Vol. 583. P. 37-42.
12. Di Daniel E., Glover C.P., Grot E., Chan M.K., Sanderson T.H., White J.H., Ellis C.L., Gallagher K. T., Uney J., Thomas J., Maycox P.R., Mudge A.W. Prolyl oligopeptidase binds to GAP-43 and functions without its peptidase activity // Mol. Cell Neurosci. 2009. Vol. 41. N 3. P. 373-382.
13. Myohanen T.T., Norrbacka S., Savolainen M. H. Prolyl oligopeptidase inhibition attenuates the toxicity of a proteasomal inhibitor, lactacystin, in the alpha-synuclein overexpressing cell culture // Neurosci. Lett. 2017. Vol. 636. P. 83-89.
14. Lashuel H.A., Overk C.R., Oueslati A., Masliah E. The many faces of alpha-synuclein: from structure and toxicity to therapeutic target // Nat. Rev. Neurosci. 2013. Vol. 14. N 1. P. 38-48.
15. Ivanova E.A., Zolotov N.N., Kapitsa I.G., Pozdnev V.F., Valdman E.A., Voronina T.A. Proline-specific endopeptidase and adenosine deaminase activity in blood serum and cerebrospinal fluid in experimental parkinson’s syndrome // Immunologiya. 2017. Vol. 38. N 4. P. 213-218.
16. Khlebnikova N.N., Krupina N.A., Bogdanova N. G., Zolotov N.N. Effect of prolyl endopeptidase inhibitor benzyloxycarbonyl-methionyl-2(s)-cyanopy-rrolidine on activity of proline-specific peptidases in brain structures of rats with experimental MPTP-induced depressive syndrome // Bull. Exp. Biol. Med. 2013. Vol. 155. N 6. P. 670-674.
17. Rocha E.M., De Miranda B., Sanders L. H. Alpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson’s disease // Neurobiol. Dis. 2018. Vol. 109. Part B. P. 249-257.
18. Руководство по проведению доклинических исследований лекарственных средств. Ч. 1 / Под ред. А.Н. Миронова. М.: Гриф и К, 2012. 944 с.
19. Blandini F., Armentero M.T. Animal models of Parkinson’s disease // FEBS J. 2012. Vol. 279. N 7. P. 1156-1166.
Review
For citations:
Kalinina A.P., Kapitsa I.G., Ivanova E.A., Voronina T.A. The antiparkinsonian action of the prolyl endopeptidase inhibitor in mice. Vestnik Moskovskogo universiteta. Seriya 16. Biologiya. 2019;74(2):87–93. (In Russ.)
Views:
322
Email this article 